每周五天"全天候交易" 全球最大交易所之一的纳斯达克交易所于当地时间周一（15日）向美国证券交易委员会（SEC）提交文 件，申请从2026年开始推出"全天候交易"服务。同时，美东时间12月17日晚，纳斯达克交易所还将迎来 美股今年最大首次公开募股（IPO）Medline。 Medline由约翰米尔斯（Jon Mills）与吉姆米尔斯（Jim Mills）兄弟于1966年创立，生产并经销医院与医 生使用的医疗耗材，包括手套、手术衣、检查台等。此次收购后，米尔斯家族仍将是公司最大个人股 东，IPO后将拥有17.8%的投票权。截至9月27日的过去九个月，公司营收206亿美元，净利润9.77亿美 元。上年同期营收187亿美元，净利润9.11亿美元。 Medline已获得基石投资者合计最多23.5亿美元的认购承诺，其他投资者还包括全球知名投资机构维京 投资（Viking Global Investors）、摩根士丹利旗下Counterpoint Global，骏利亨德森（Janus Henderson Investors）、Baillie Gifford、Capital Group，以及新加坡主权财富基金GIC等。高盛 ...

每周五天"全天候交易" 纳斯达克提供的数据显示，美股市场市值约占全球上市公司总市值的三分之二，截至去年，外国投资者 持有的美股总额已达17万亿美元。 全球最大交易所之一的纳斯达克交易所于当地时间周一（15日）向美国证券交易委员会（SEC）提交文 件，申请从2026年开始推出"全天候交易"服务。同时，美东时间12月17日晚，纳斯达克交易所还将迎来 美股今年最大首次公开募股（IPO）Medline。 因此，为满足投资者对美股不间断交易需求的增加，早在今年3月，纳斯达克交易所总裁可汗（Tal Cohen）就曾表示，交易所已启动与监管机构的磋商，预计于2026年下半年推出每周五天的不间断交易 服务。此次提交SEC文件，标志着纳斯达克正式启动每周五天全天候交易的推进进程。纳斯达克北美市 场高级副总裁迈克（Chuck Mack）表示："交易全球化趋势已持续一段时间，而美国市场本身也变得越 来越具全球性。" 纽约证券交易所和芝加哥期权交易所近期也宣布了类似的股票全天候交易计划。 根据计划，纳斯达克将把股票和交易所交易产品（ETPs）的每日交易时间从目前的16小时延长至23小 时，每周运行五天。目前纳斯达克在工作日设有三个交 ...

智通财经APP获悉，今年美国最大IPO诞生——Medline Inc.(MDLN.US)筹资62.6亿美元。该次IPO发行 规模经上调后，最终定价锁定在推介区间高位，具体以每股29美元发行2.16亿股股票。此次扩大的发行 计划于2025年12月17日晚些时候正式登陆纳斯达克交易所，股票代码"MDLN"。按提交给美国证券交易 委员会(SEC)的股票数量计算，此次定价对应的公司市值约为390亿美元。 据了解，Medline现有股东阵容涵盖黑石集团(Blackstone Inc.)、凯雷集团(Carlyle Group Inc.)及Hellman & Friedman三大私募巨头。回溯至2021年，这三家机构曾以340亿美元联合收购Medline多数股权，成为史 上规模最大的杠杆收购之一。 此外，Medline已获得基石投资者合计最多23.5亿美元的认购承诺，投资者包括全球知名投资机构Baillie Gifford、Capital Group、摩根士丹利旗下Counterpoint Global、Durable Capital Partners，以及新加坡主权 财富基金GIC、Janus Henderson Inv ...

来源：新浪证券-红岸工作室 12月16日，采纳股份跌3.28%，成交额7478.06万元，换手率3.46%，总市值34.19亿元。 区间今日近3日近5日近10日近20日主力净流入55.69万489.58万738.57万1493.98万1453.75万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额801.27万，占总成交额的2.39%。 异动分析 辅助生殖+医疗器械概念+人民币贬值受益 1、公司采纳医疗于2018年开始向Thermo Fisher 供应试管婴儿培育管产品。 2、公司主营业务为从事注射穿刺器械及实验室耗材的研发、生产和销售。公司目前主要产品为穿刺 针、注射器、实验室耗材及口罩等。 3、根据2024年年报，公司海外营收占比为90.61%，受益于人民币贬值。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入55.69万，占比0.01%，行业排名27/132，连续2日被主力资金增仓；所属行业主力净流 入-3.47亿，当前无连续增减仓现象，主力趋势不明显。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包 ...

Core Viewpoint - Wuzhou Medical experienced a decline of 3.88% in stock price on December 16, with a trading volume of 145 million yuan and a market capitalization of 2.965 billion yuan [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion sets, and other related medical supplies [2][7] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the period from January to September 2025, representing a year-on-year growth of 0.82%, while the net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company's overseas revenue accounted for 96.88% of total revenue, benefiting from the depreciation of the RMB [3] - The average trading cost of the stock is 42.62 yuan, with the current stock price near a support level of 43.15 yuan, indicating potential for a rebound if this support holds [6] - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Activity - On the trading day mentioned, the main net inflow of funds was 7.6572 million yuan, accounting for 0.05% of the total, with the industry ranking at 7 out of 132 [4] - The stock has seen a continuous increase in main funds over the past three days, although the overall trend remains unclear [5]

Core Viewpoint - Wuzhou Medical has seen a 4.44% increase in stock price, with a trading volume of 151 million yuan and a market capitalization of 3.085 billion yuan, indicating positive market sentiment towards the company [1] Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices, including various types of syringes, infusion sets, blood transfusion devices, and other related medical supplies [2] - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which signifies its strong market position and innovation capabilities [2] - As of October 20, the company reported a revenue of 345 million yuan for the first nine months of 2025, reflecting a year-on-year growth of 0.82%, while the net profit attributable to shareholders decreased by 46.09% to 18.51 million yuan [7] Group 2: Financial Performance - The company’s overseas revenue accounts for 96.88% of total revenue, benefiting from the depreciation of the Chinese yuan [3] - The average trading cost of the stock is 42.55 yuan, with the current stock price fluctuating between resistance at 47.98 yuan and support at 43.15 yuan, suggesting potential for short-term trading strategies [6] - Wuzhou Medical has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Activity - The stock has experienced a net inflow of 3.86 million yuan from major investors today, with a total of 95.76 million yuan net inflow in the industry over the past two days [4][5] - The stock's trading volume indicates a dispersed distribution of shares among major investors, with major transactions accounting for 7.61% of total trading volume [5]

5、公司属于国有企业。公司的最终控制人为厦门市人民政府国有资产监督管理委员会。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 1、2024年度可持续发展（ESG）报告：提出"六防"核辐射防护手套的技术需求，与桂林理工大学联合 研发团队进行为期一年的科技攻关，对标先进企业核辐射防护手套产品的结构及性能，研发出具有化学 防护层、白色警示层、核辐射防护层和穿戴内层的多层核辐射防护手套的关键材料体系和成型工艺。 2、2025年3月3日官微：中红医疗亮相第12届京宠展。中红普林医疗用品股份有限公司（以下简称"中红 医疗"）携旗下健康防护、安全输注、创新孵化产品出席，其中迈德瑞纳宠物泵，备受瞩目。展会上， 中红医疗旗下迈德瑞纳 UniFusion SP50 Vet 及 UniFusion VP50 Vet 兽用输注泵备受关注，两款产品具备 IP34 防水设计和双 CPU 架构，能提供多种输液模式及微量模式最大流速设置，兼顾安全与多功能性。 兽医现场体验后表示，输注泵操作便捷，可切换电池或电源运行，能提供精准、安全、易用的输液方 案，适配多种场景，是临床工作必备。 3、公司主营业务产品以 ...

Core Viewpoint - Wuzhou Medical has shown a slight increase in stock price and has been recognized as a "specialized, refined, distinctive, and innovative" enterprise, which enhances its competitive edge in the medical device industry [2][3]. Company Overview - Wuzhou Medical, established on April 15, 2011, and listed on July 5, 2022, specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies [7]. - The company's revenue composition includes 41.29% from syringes, 25.51% from medical puncture needles, 20.92% from infusion and blood transfusion devices, and 12.28% from other products [7]. - As of October 20, 2023, the company had 5,489 shareholders, an increase of 17.31%, with an average of 7,318 circulating shares per person, a decrease of 14.76% [7]. Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, representing a year-on-year growth of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a decrease of 46.09% year-on-year [7]. - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8]. Market Position and Trends - Wuzhou Medical's main business benefits from the depreciation of the RMB, with overseas revenue accounting for 96.88% of total revenue [3]. - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables, and is part of several concept sectors including specialized and innovative enterprises, financing, and small-cap stocks [7]. Trading Activity - On December 12, 2023, Wuzhou Medical's stock rose by 0.91%, with a trading volume of 83.52 million yuan and a turnover rate of 4.81%, leading to a total market capitalization of 2.954 billion yuan [1]. - The stock has seen a net inflow of 8.06 million yuan from major investors, indicating a positive trend over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 42.39 yuan, with the current price approaching a support level of 43.15 yuan, suggesting potential for a rebound if this level holds [6].

来源：新浪证券-红岸工作室 12月12日，中红医疗跌3.21%，成交额1.24亿元，换手率2.29%，总市值58.15亿元。 异动分析 核污染防治+宠物经济+国企改革+医疗器械概念+人民币贬值受益 1、2024年度可持续发展（ESG）报告：提出"六防"核辐射防护手套的技术需求，与桂林理工大学联合 研发团队进行为期一年的科技攻关，对标先进企业核辐射防护手套产品的结构及性能，研发出具有化学 防护层、白色警示层、核辐射防护层和穿戴内层的多层核辐射防护手套的关键材料体系和成型工艺。 2、2025年3月3日官微：中红医疗亮相第12届京宠展。中红普林医疗用品股份有限公司（以下简称"中红 医疗"）携旗下健康防护、安全输注、创新孵化产品出席，其中迈德瑞纳宠物泵，备受瞩目。展会上， 中红医疗旗下迈德瑞纳 UniFusion SP50 Vet 及 UniFusion VP50 Vet 兽用输注泵备受关注，两款产品具备 IP34 防水设计和双 CPU 架构，能提供多种输液模式及微量模式最大流速设置，兼顾安全与多功能性。 兽医现场体验后表示，输注泵操作便捷，可切换电池或电源运行，能提供精准、安全、易用的输液方 案，适配多种场景，是临 ...

Core Viewpoint - The company, Wuzhou Medical, is experiencing a decline in stock price and trading volume, while benefiting from its status as a "specialized, refined, distinctive, and innovative" enterprise and the depreciation of the RMB, which positively impacts its overseas revenue. Group 1: Company Overview - Wuzhou Medical specializes in the research, production, and sales of disposable sterile infusion medical devices and related medical supplies, including various types of syringes and infusion devices [2][7] - The company was established on April 15, 2011, and went public on July 5, 2022 [7] - As of October 20, the company had 5,489 shareholders, an increase of 17.31%, with an average of 7,318 circulating shares per person, a decrease of 14.76% [7] Group 2: Financial Performance - For the period from January to September 2025, Wuzhou Medical achieved a revenue of 345 million yuan, a year-on-year increase of 0.82%, while the net profit attributable to the parent company was 18.51 million yuan, a year-on-year decrease of 46.09% [7] - The company has distributed a total of 81.6 million yuan in dividends since its A-share listing [8] Group 3: Market Position and Trends - Wuzhou Medical is recognized as a "little giant" enterprise, which signifies its strong innovation capabilities and high market share in niche markets [2] - The company’s overseas revenue accounts for 96.88% of its total revenue, benefiting from the depreciation of the RMB [3] - The main business revenue composition includes syringes (41.29%), medical puncture needles (25.51%), and infusion and blood transfusion devices (20.92%) [7] Group 4: Technical Analysis - The average trading cost of the stock is 42.36 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6] - The current stock price is near a resistance level of 43.15 yuan, indicating potential for a pullback unless this level is broken [6]